Home Apoptosis RIP kinase

RIP kinase

Other Apoptosis Related Inhibitors

Caspase Bcl-2 p53 Ferroptosis PD-1/PD-L1 Survivin TNF-alpha MDM2/MDMX KRas IAP

Isoform-selective Products

Cat.No. Product Name Information Product Use Citations Product Validations
S8037 Necrostatin-1 (Nec-1) Necrostatin-1 (Nec-1) is a specific RIP1 (RIPK1) inhibitor and inhibits TNF-α-induced necroptosis with EC50 of 490 nM in 293T cells. Necrostatin-1 also blocks IDO and suppresses autophagy and apoptosis.
FEBS J, 2026, 10.1111/febs.70467
Cell Res, 2025, 10.1038/s41422-025-01167-8
Signal Transduct Target Ther, 2025, 10(1):341
Verified customer review of Necrostatin-1 (Nec-1)
S8641 Necrostatin 2 racemate (Nec-1s) Necrostatin 2 racemate (Nec-1s, 7-Cl-O-Nec1, Necrostatin-1 stable, Necrostatin 1S) is a stable variant of Necrostatin-1. This compound is a more specific RIPK1 inhibitor lacking the IDO-targeting effect, with >1000-fold more selective for RIPK1 than for any other kinase out of 485 human kinases.
Neural Regeneration Research, Not available, Not available
Cell Reports, June 15, 2021, 109235
Journal of Virology, June 13, 2022, Not available
S8465 GSK872 GSK'872 is a potent and selective RIP3 kinase inhibitor which binds RIP3 kinase domain with high affinity (IC50=1.8 nM) and inhibits kinase activity with IC50 of 1.3 nM. It has minimal cross-reactivity.
Acta Biochimica Polonica, July 10, 2022, 485-494
bioRxiv, February 06, 2026, nan
Cell Death Discovery, December 07, 2025, nan
Verified customer review of GSK872
S9733 Mito-TEMPO Mito-TEMPO (MT), a mitochondria-targeted superoxide dismutase mimetic, protects against the early phase of acetaminophen (APAP) hepatotoxicity by inhibiting peroxynitrite formation. Mito-TEMPO treatment inhibits APAP-induced RIP3 kinase expression.
Frontiers in Pharmacology, September 25, 2023, 1128312
Clin Transl Med, 2025, 15(1):e70180
J Biol Chem, 2025, 301(10):110653
S8642 GSK'963 GSK'963 is a chiral small-molecule inhibitor of RIP1 kinase (RIPK1) with an IC50 of 29 nM in FP binding assays. It is >10 000-fold selective for RIP1 over 339 other kinases.
Proceedings of the National Academy of Sciences, February 18, 2025, e2420802122
eLife, December 06, 2021, e73137
PLoS Biol, 2025, 23(2):e3002845
S6511 RIPA-56 RIPA-56 is a highly-potent, selective, and metabolically stable RIP1 (RIPK1) inhibitor.
Journal of Oncology, July 11, 2022, 2390078
Acta Pharmaceutica Sinica B, January 2024, 319-334
European Journal of Pharmacology, December 15, 2022, 175381
S8484 GSK2982772 GSK2982772 is an ATP competitive receptor-interacting protein-1 (RIP1) kinase (RIPK1) inhibitor with the IC50 value of 16 nM. It has exquisite kinase specificity and excellent activity in blocking many TNF-dependent cellular responses.
Antioxidants, 2021, 1347
Antioxidants (Basel), 2021, 10(9)1347
Mol Cell Biochem, 2021, 10.1007/s11010-021-04136-y
S8261 GSK583 GSK583 is a highly potent and selective inhibitor of RIP2 kinase with IC50 of 5 nM. This compound also inhibits both TNF-α and IL-6 production with IC50 of ~200 nM in explant cultures.
Journal of Medicinal Chemistry, 2025 Mar 13, 5529-5550
J Invest Dermatol, 2025, S0022-202X(25)00494-4
Dissertation, Universität Regensburg, 2022, Unknown
S3238 Resibufogenin Resibufogenin (Bufogenin, Recibufogenin), a component of huachansu with anticancer effect, triggers necroptosis through upregulating receptor-interacting protein kinase 3 (RIP3) and phosphorylating mixed lineage kinase domain-like protein at Ser358. This compound exerts cytotoxic effect by inducing reactive oxygen species (ROS) accumulation. It induces apoptosis and caspase-3 and caspase-8 activity. This chemical increases Bax/Bcl-2 expression, and suppresses cyclin D1, cyclin E, PI3K, p-AKT, p-GSK3β and β-catenin protein expression.
bioRxiv, 2025, 2025.07.17.665404
Research Square, 2024, 10.21203/rs.3.rs-3790060/v1
Phytomedicine, 2022, 102:154182
S6078 ICCB-19 hydrochloride ICCB-19 hydrochloride is an inhibitor of TNFRSF1A Associated Via Death Domain (TRADD) with IC50 of 1.12 μM and 2.01 μM for protecting Velcade-induced apoptosis in Jurkat cells and protecting RDA in MEFs, respectively. ICCB-19 indirectly inhibits Receptor-interacting serine/threonine-protein kinase 1 (RIPK1). ICCB-19 effectively induces autophagy.
The EMBO Journal, 2025, 6196-6225
EMBO J, 2025, 10.1038/s44318-025-00561-7
The EMBO Journal, 2025, 6196-6225